Journal Home
Search for

Volume 43, Issue 1, Pages 31-39 (February 2009)


View previous. 5 of 8 View next.

Changes in the NPY immunoreactivity in gerbil hippocampus after hypoxic and ischemic preconditioning

Malgorzata Duszczyka, Apolonia Ziembowicza, Roman Gadamskia, Joanna M. Wieronskab, Maria Smialowskab, Jerzy W. LazarewiczaCorresponding Author Informationemail address

Received 30 June 2008; accepted 28 September 2008. published online 14 November 2008.

Abstract 

Preconditioning with sublethal ischemia or hypoxia may reduce the high susceptibility of CA1 pyramidal neurons to ischemic injury. In this study, we tested the hypothesis that enhanced level of neuropeptide Y (NPY) might play a role in the mechanisms responsible for this induced tolerance. Changes in NPY immunoreactivity in the hippocampal formation of preconditioned Mongolian gerbils were compared with the level of tolerance to test ischemia. Tolerance was induced by preconditioning with 2-min of ischemia or with three trials of mild hypobaric hypoxia (360Torr, 2h), separated by 24h, that were completed 48h before the 3-min test ischemia. The number of NPY-positive neurons in the gerbil hippocampal formation was assessed 2, 4 and 7days after preconditioning. Survival of the CA1 pyramidal neurons was examined 14days after the insult. Our experiments demonstrated that ischemic and hypoxic preconditioning produced equal attenuation of the damage evoked by 3-min ischemia, although the pattern of NPY immunoreactivity in the hippocampus differed. Preconditioning ischemia resulted in a 20% rise in the number of NPY-positive neurons 2days later that disappeared 4days after the ischemic episode, while mild hypobaric hypoxia induced a twofold increase in the number of NPY-positive neurons that lasted for at least 7days. Although induced tolerance to ischemia 2days after ischemic or hypoxic preconditioning was accompanied by increased immunoreactivity of NPY, there was no correlation between its intensity and the level of neuroprotection.

a Medical Research Centre, Polish Academy of Sciences, 5 Pawinskiego Street, Warsaw 02-106, Poland

b Institute of Pharmacology, Polish Academy of Sciences, 12 Smetna Street, Cracow 31-343, Poland

Corresponding Author InformationCorresponding author. Tel.: +48 22 608 65 28; fax: +48 22 668 54 23.

PII: S0143-4179(08)00109-1

doi:10.1016/j.npep.2008.09.008


View previous. 5 of 8 View next.